艾美健康科技有限公司 2025年季度报告

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from toCommission File Number:001-41880 New York,NY10022(Address of principal executive offices) (Zip Code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Months Ended Net income$184,662$Adjustments to reconcile net income to net cash used in operating activities:Interest earned in assets held in trust(598,076)(909,132)Change in operating assets and liabilities:Prepaid expenses1,499Due to a related company30,000 Cash withdrawn from Trust Account in connection to redemption31,265,500Extension payments deposited in Trust Account(477,700) 30,787,800Cash flows from financing activities:Proceeds from extension promissory note – related party477,700Advance from related party203,146Redemption of ordinary shares(31,265,500) NET CHANGE IN CASH(20,863)(166,970)CASH, BEGINNING OF PERIOD28,808CASH, END OF PERIOD$7,345$ The accompanying notes are an integral part of these unaudited financial statements. Aimei Health Technology Co., Ltd. (the “Company”) is a blank check company incorporated in the Cayman Islands onApril 27, 2023.TheCompany was formed for the purpose of entering into a merger,share exchange,asset acquisition,share purchase,recapitalization, reorganization or similar business combination with one or more businesses or entities. Although there is no companies and in drug and device technology development as well as diagnostic and other services.As of March 31, 2025, the Company had not yet commenced any operations. All activities through March 31, 2025 related to theCompany’s formation and the Initial Public Offering (as defined below). Since the Initial Public Offering, the Company’s activity hasbeen limited to the costs in pursuit of the consummation of an initial business combination. The Company will not generate anyoperating revenue until after the completion of its initial business combination, at the earliest. The Company will generate non- being offered, the “Public Shares”), at $10.00per Unit, which includes full exercise of the underwriters’ over-allotment optionof900,000 Units, generating gross proceeds of $69,000,000(the “Initial Public Offering”), and incurring offering costs of$2,070,665and $690,000for deferred underwriting commissions (see Note 7). The Company granted the underwriters a 45-day optionto purchase up to an additional900,000Units at the Initial Public Offering price to cover over-allotments, if any. On December 6, Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of anaggregate of332,000units (the “Private Units”) to the Sponsor at a price of $10.00per Unit, generating total gross proceeds of$3,320,000(the “Private Placement”). (see Note 4).Following the closing of the Initial Public Offering on December 6, 2023, an amount of $69,690,000($10.10per Unit) from the netproceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Private Units wasplaced in a trust account (the “Trust Account”), located in the United States and held as cash items or may be invested only in U.S.government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditionsunder Rule 2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries, as determined by the Company, untilthe earlier of: (i) the consummation of a business combination, or (ii) the distribution of the funds in the Trust Account to the The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially$10.10per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company by the deferred underwriting commissions the Company will pay to the underwriter. There will be no redemption rights upon thecompletion of a business combination with respect to the Company’s rights.5 Company will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant toRule 13e-4 and Regulation 14E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which regulate issuer The Sponsor has agreed (i) to vote any shares owned by them in favor of any proposed business combination, (ii) not to redeem anyshares in connection with a shareholder vote to approve a proposed initial business combination or any amendment to the Company’scharter prior to the consummation of its initial business combination and (iii) not to sell any shares to the Company in a tender offer inconnection with any proposed business combination. However, the Spo